ALNY logo

Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
ALNY
ISIN Code
US02043Q1076
Currency
US Dollar (USD)
IPO Date
2004-05-28

Contact Information

Company Address
675 West Kendall Street, Cambridge, MA, United States, 02142
Contact Phone
617 551 8200
Company Website
https://www.alnylam.com
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$999,999.99
Return on Assets (TTM)
12.34%
EBITDA
$999,999.99
Revenue (TTM)
$999,999.99